At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 519 enrolled
Drug / intervention
Bowel Prepdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety and Efficacy Comparison of BLI4900 Bowel Preparation Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy
In Brief
A Phase 3 clinical trial evaluating Bowel Prep for Colonoscopy. Completed, enrolled 519 participants across 25 sites.
Detailed Summary
The purpose of this study is to compare the safety and efficacy of BLI4900 bowel preparation to an FDA-approved control as 2-day, split-dose bowel preparations prior to colonoscopy in adult patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColonoscopy
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJul 2020
Primary CompletionDec 2020
Study CompletionJan 2021
TodayJul 2026
First PostedJun 24, 2020
Enrollment StartJul 13, 2020
Primary CompletionDec 22, 2020
Study CompletionJan 22, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.0 years ago
Interventions
Bowel Prepdrug
Orally ingested liquid bowel preparation